Human papillomavirus vaccine

The quadrivalent human papillomavirus vaccine is recommended as a three-dose series (0, 2, and 6 months) for all females 11 to 12 years old. The vaccine is licensed for females 9 to 26 years of age. 

Lowy DR, Schiller IT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006 116(5) 1167-73. 

Tazicef, Waytrax Cervarix human papillomavirus vaccine (bivalent )... 

Lehtinen, M. and Dillner, J. (2002). Preventive human papillomavirus vaccination. Sex. Transm. Infect. 78, 4-6. 

Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, Bohle A, Brandau S (2006) Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66 8250-8257 Tindle RW (1996) Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 8 643-650 Tobinai K (2007) 4. Antibody therapy for malignant lymphoma. Intern Med 46 99-100... 

Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus a case-conbol study. Ann Rheum Dis 2013 72(5) 659-64. 

A new subunit recombinant vaccine is Gardasil it is a tetravalent vaccine against human papillomavirus (HPV) implicated in cervical cancer. See Exhibit 4.5 for details. 

Gardasil is a noninfectious recombinant vaccine consisting of capsid proteins from four different human papillomaviruses (HPVs) of types 6,11, 16, and 18. HPV causes squamous cell cervical cancer and cervical adenocarcinoma, as well as 35-50% of vulvar and vaginal cancers. 

Hqjatitis B Vaccine (Engerix-B, Recombivax HB) Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil)... 

Human papillomavirus (HPV) infection is a necessary factor in the development of nearly all cases of cervical cancer. A recently approved HPV vaccine, Gardasil, that blocks initial infection with several of the most common sexually transmitted HPV types may lead to significant decreases in the incidence of HPV-induced cancer (see Lowy et ah, 2006). 

Human papillomavirus (HPV) is the causative agent of virtually all cases of cervical cancer and one of the most common of the sexually transmitted diseases. Cervical cancer remains a main cause of cancer-related death in many developing countries. Current vaccines are too expensive... 

Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil) [Vaccine] Uses Prevent cervical CA, precancer-ous genital lesions, and genital warts d/t HPV types 6, 11, 16, 18 in females 9-26 y Action Recombinant vaccine, passive humoral immunity Dose 0.5 mL EM initial, then 2 and 6 mo observe for 15 min after, keep seated or lying down Caution [B, /-] Disp Inj SE Site Rxn (pain, erythema, swelling, pruritus), fever, fainting w/ administration Interactions W/ immunosuppressants, may get decreased response EMS Convulsive syncope (fainting associated w/ Sz -like activity) OD Unlikely... 

Chen, C.H., Ji, H., Suh, K.W., Choti, M.A., Pardoll, D.M. and Wu, T.C. (1999) Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther., 6, 1972-1981. 

Tan, J., Yang, N.S., Turner, J.G., Niu, G.L., Maassab, H.F., Sun, J. etal. (1999) Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Then, 6, 331-339. 

---